Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?

Table 1 Autologus hemapoietic stem cells transplantation studies in Crohn's disease

Ref.	Patients (n)	Follow up(mo)	Deaths	Remission(number of patients, time of evaluation in months)	Recurrence(number of patients or %, time of evaluation in months)
Oyama et al[24]	12	18.5 mo (7-37)	No	Clinical 11 (12 mo)	1% (18.5 mo)
Burt et al[25]	24	60 mo	1 not related	Clinical 24 (6-12 mo)	9% (12 mo)
					37% (24 mo)
					43% (36 mo)
					61% (48 mo)
					81% (60 mo)
Cassinotti et al[26]	10	56 mo (23-68)	No	Clinical 10 (3 mo) Endoscopic 5 (3 mo)	20% (12 mo)
					50% (24 mo)
					60% (36 mo)
					70% (48 mo)
					70% (60 mo)
Hasselblatt et al[27]	12	37 mo (IQR 6-123)	No	Clinical 4/8 (6 mo) Endoscopic 5/9 (9.1 mo) 3/9 mild disease	7% (10.9 mo)
Hawkey[28]	Data from 30 out of 45 patients 16 mobilisation + HCST (A) 16 mobilisation (B)		1 death after HCST	NA A: CDAI fell 162 (IQR 0-190) B: CDAI fell 82 (IQR 41-137)	NA
Jauregui-Amezaga et al[29]	21 evaluable	12 mo	1 after CMV infection and multiorganic failure	NA	NA

NA: Not available; CDAI: Crohn´s disease activity index; IQR: Interquartile range; CMV: Cytomegalovirus.